Sysmex Europe GmbH, which oversees Sysmex’s operations in EMEA (Europe, Middle East & Africa), has announced its Chairman and long-time President & CEO Dr Jürgen Schulze decided in early 2018 to retire effective 30 September 2018, however will continue to benefit and support Sysmex as a member and vice-chairman of the MedTech Europe Executive Board.
Dr Schulze began his Sysmex journey in 1995, stepping in as the Managing Director for Sysmex Germany, the first direct affiliate of EMEA headquarters. He was in this role until 2009 and was instrumental in Sysmex Germany’s tremendous growth, which played a large part in Sysmex becoming a market leader in haematology. Dr Schulze then became a member of the Senior Management Team EMEA, and eventually became an Executive Officer of Sysmex Corporation (Japan). His active role in relevant industry associations helped augment his expertise and knowledge of current market trends and directions.
After a dynamic and successful career, Dr Schulze has decided it is time to start a new chapter of his life. Sysmex is grateful for his many years of hard work and dedication that resulted in the strong continuous growth the company has experienced in EMEA.
Dr Schulze has passed the baton onto Alain Baverel, who has been transitioning into his role as President & Chief Executive Officer Sysmex EMEA since April 2018, with his fully-fledged role officially beginning on 1 October 2018. Mr Baverel joined Sysmex in 2007 as Managing Director of the newly established affiliate Sysmex France S.A.S. During his 10 years’ experience as the president of Sysmex France, they also saw extraordinary growth and developed a strong foundation and reputation in the local market.
In alignment with the 2025 vision for advancement from Sysmex Corporation – the global headquarters in Kobe, Japan – to become a global top-five company in in vitro diagnostics, Mr Baverel plans to fully support Sysmex Europe in achieving this goal. He believes this goal can be reached by addressing the crucial element of optimising patient treatment and personalised medicine as well as differentiating from others by means of innovative business models. He also acknowledges that taking risks is vital, as well as recognising that the true value of a business is the commitment of its people.
With 25 years’ experience in the diagnostic technology industry, Mr Baverel has a strong understanding of this field. With the state of the business world constantly evolving, Mr Baverel’s experience both before and during his time at Sysmex will help advance the company even further.
